Search Results
Results found for "Glaxo Inc"
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
Kenakin acknowledges the increasing utility of in silico alerts in early decision-making, arming medicinal
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition; 2025 Fellows announced, including FAQ 🔹 What’s included?
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
. 👉 This kind of failure is hard to detect because it hides behind familiar patterns: Incremental scope Activity increases while coherence declines . Effort increases.
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
unexpected distribution profiles forced complete strategic pivots Plasma concentration alone is an incomplete
- The Hidden Cost of Unclear Biotech Positioning
Business development conversations feel inconsistent, even when the company and the science have not This inconsistency is not random. meetings with different interpretations of what the company actually is , which slows momentum and increases Each external interaction becomes reactive, shaped more by incoming questions than by strategic intent Scientific depth increases complexity.
- How Early Strategic Decision Making Creates Alignment and Better Results
. ✅ Early strategic decision-making does not guarantee success, but it dramatically increases the odds Biotech teams operate across disciplines, timelines, and incentives.
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
It is building a team that cannot operate when answers are incomplete. ✅ This is where survival is decided They look for certainty before committing. 👉 This is not incompetence. Progress depends on decisions made with incomplete information. The Difference Between Competent and Useful in Early Stage Biotech As uncertainty increases, a subtle
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
Common signals include: 👉 Patents focused on one indication, while the business story targets another Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights That uncertainty increases perceived risk, even if the underlying science is compelling. Intellectual property is increasingly evaluated together with development plans and commercial intent
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
. 👉 BD partners disengage because timing and readiness seem inconsistent. 👉 Teams hedge their work But what kills momentum is timing inconsistency . 👉 Without a defined decision cadence: Choices get conversations that lack mutual timing expectations internal teams working with partial context narrative inconsistency
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Premium Membership pricing increases in 2026, and the 67% Terry’s Corner discount is going away. This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. contributors Launch of The Foundry , supporting strategy and CRO alignment In-person community moments, including
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
You may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
In this episode, JB pulls the curtain back on the mindset and tactics he’s used for years—including the
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
AI-assisted probe design Multi-receptor visualization in complex tissue The dream is ambitious and increasingly
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
They are signs of strategic incompleteness .
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
Live-cell high-content screening (HCS) offers an increasingly valuable alternative. , 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using a CB2 live-cell HCS assay incorporating Because imaging is captured across thousands of intact cells, each measurement incorporates receptor Moderate displacement (50–70%) : AV18A (68.83%), AV11 (60.78%) Low displacement (<50%) : Compounds including Representative HCS images illustrating CELT331 binding (red) and Hoechst-stained nuclei (blue) across increasing
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
When David later shared early data — including a moment where he realized he could image an entire islet Antibodies As JB continued exploring the biology, a major obstacle emerged: validated antibodies for GPCRs, including GLP-1R, were inconsistent and incompatible with high-resolution imaging. David picked up unexpected chemistry insights — including a well-loved lesson involving acetonitrile They’re also performing increasingly complex imaging experiments that capture receptor dynamics in intact
- How System-Level GPCR Thinking Prevents Discovery Failures
FAQ 🔹 What’s included?
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Orthosteric dose increases drive continuously stronger responses; NAMs and PAMs have structural ceilings A partial agonist appears neutral until expression or coupling is increased. Dr. NAMs, PAMs, and Subtle Mechanistic Traps Modulators are frequently labeled correctly but characterized incompletely These nonlinearities matter: Competitive inhibition decreases as substrate increases. Uncompetitive inhibition strengthens as substrate increases—opposite of intuition.
- How Collaboration Drives GPCR Discoveries
In research, including the GPCR world collaboration isn’t a luxury. It’s survival. To understand how incretin receptors behave in intact tissue, Hodson needed people who saw problems differently Hodson’s group felt the impact directly: imaging incretin receptors in intact islets and brain slices And interactions with GLP-1 pathways were inconsistent.
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
several performance-limiting factors: variable cell behavior, imaging artifacts, batch effects, and incomplete In this blog, you’ll learn: How HCS works and why it is increasingly central to GPCR-based drug discovery However, their limitations become increasingly important as drug discovery moves toward high-information Key limitations of radioligand assays include: • No spatial information — signals are measured in bulk Incorporating internal controls, including known agonists or antagonists, allows normalization and facilitates
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Here, the Schild plot becomes a diagnostic tool rather than a checkbox test: Slopes >1 often mean incomplete Common revelations include: Mixtures of receptor subtypes producing hybrid response patterns. Incomplete equilibration , where kinetics distort linearity.
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
In research, acting on incomplete or shaky data can destroy your credibility. Startups demand something different: ✅ Clarity of direction even when the picture is incomplete.
- How GPCR Collaboration Built an Innovation Engine
scientists embedded as “connectors” between programs This design had a strategic effect : talent density increased notes that the absence of individual ownership over physical space or specialized equipment removed the incentives Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives
- From Pipettes to Platforms: The Evolution of GPCR Research
These weren’t quaint inconveniences. They shaped how questions were asked.
- Molecular creativity in drug discovery
. • Inclusive Growth : More access for developing nations, new instructors welcome, and global partnerships FAQ 🔹 What’s included?
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
drug matter beyond the familiar and encourages deliberate exploration of chemical novelty, rather than incremental They offer high specificity , favorable safety , and unique mechanisms , including GPCR modulation through
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
partners, and GPCR experts to help teams move faster — from idea to discovery — while reducing risk and increasing The Foundry will also include Yamina’s Consulting Corner — a place for teams to get tailored scientific For the first time, University courses will be included in Premium Membership , giving members full access GPCR is evolving — thoughtfully, inclusively, and sustainably.
- GPCR Collaboration: From Models to Medicine
Over time, that transparency has built enduring partnerships , including one of Carlsson’s earliest with explain why collaborators return, why projects move forward, and why his model of collaboration is increasingly
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
Common questions in the group include: Can we forecast ligand efficacy or selectivity?
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Allosteric modulators and biased ligands aren’t exotic outliers—they’re increasingly common outcomes





























